New Cancer Treatment Rival: Proton Therapy Matches Radiation, Cuts Side Effects
Groundbreaking research from The University of Texas MD Anderson Cancer Center reveals that intensity modulated proton therapy (IMPT) offers head and neck cancer patients the same survival rates as the standard intensity modulated radiation therapy (IMRT) — but with fewer nasty side effects.
The findings dropped today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, presented by Dr. Steven Frank, MD Anderson’s Radiation Oncology chief and Particle Therapy Institute director.
IMPT vs IMRT: The Head-to-Head Results
- Survival Rates Neck to Neck: After a median follow-up of three years, IMPT patients showed an 83% progression-free survival rate, closely matching IMRT’s 83.5%.
- Less Malnutrition: Just 24% of IMPT patients lost under 5% of their weight during treatment, a much safer figure compared to 14% in the traditional therapy group.
- Fewer Feeding Tubes: Only 28% of IMPT patients needed feeding tubes versus 42% of those on IMRT — a big boost for patient quality of life.
Why This Matters: A New Standard of Care?
Dr. Frank hailed the results as a “curative, de-intensified option” that might soon become the new go-to for head and neck cancers. “This multi-center Phase III trial backs IMPT as a standard treatment, promising fewer complications without compromising effectiveness,” he said.
What Makes Proton Therapy Special?
Unlike conventional radiation, proton therapy zeroes in on tumours with pinpoint accuracy, sparing healthy tissue nearby. This precision is what’s driving excitement around IMPT in cancer care.
The study is the largest Phase III trial comparing proton therapy to traditional radiation, elevating IMPT as a serious contender in the fight against cancer.
